KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Gains from Sales and Divestitures (2021 - 2023)

Ginkgo Bioworks Holdings filings provide 3 years of Gains from Sales and Divestitures readings, the most recent being $4000.0 for Q2 2023.

  • On a quarterly basis, Gains from Sales and Divestitures fell 99.08% to $4000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $4000.0, a 99.08% decrease, with the full-year FY2022 number at $136.2 million, up 57500.35% from a year prior.
  • Gains from Sales and Divestitures hit $4000.0 in Q2 2023 for Ginkgo Bioworks Holdings, roughly flat from $4000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $136.2 million in Q4 2022 to a low of $4000.0 in Q1 2023.
  • Median Gains from Sales and Divestitures over the past 3 years was $236427.0 (2021), compared with a mean of $19.7 million.
  • Biggest five-year swings in Gains from Sales and Divestitures: surged 57500.35% in 2022 and later tumbled 99.08% in 2023.
  • Ginkgo Bioworks Holdings' Gains from Sales and Divestitures stood at $236427.0 in 2021, then surged by 57500.35% to $136.2 million in 2022, then plummeted by 100.0% to $4000.0 in 2023.
  • The last three reported values for Gains from Sales and Divestitures were $4000.0 (Q2 2023), $4000.0 (Q1 2023), and $136.2 million (Q4 2022) per Business Quant data.